Cleve Clin J Med
April 1, 2025
Nicole Cornish, Tara Coles, M. Jennifer Cheng et al.
3 citations
Psychedelic-assisted therapy clinical trials conducted over the past decade have prompted increased interest in the use of psychedelics to treat nonphysical suffering, which can include significant spiritual and existential distress at the end of life. The authors explore the role of psychedelics in helping to address patients' spiritual and existential suffering from a medical, ethical, and...
The American journal of psychiatry
2025
Aaron Wolfgang, Gregory A. Fonzo, Joshua C. Gray et al.
47 citations
MDMA (i.e., 3,4-methylenedixoymethamphetamine), commonly known as "Ecstasy" or "Molly," has been used since the 1970s both in recreational and therapeutic settings. The Food and Drug Administration (FDA) designated MDMA-Assisted Therapy (MDMA-AT) as a Breakthrough Therapy for posttraumatic stress disorder (PTSD) in 2017, and the FDA is requiring an additional phase 3 trial after rejecting the...
American Journal of Psychiatry
2025
Adrienne Grzenda, Gregory A. Fonzo, Aaron Wolfgang et al.
14 citations
The evidence is currently insufficient to recommend psilocybin with PST as a psychiatric treatment. Additional rigorously designed clinical trials are needed to definitively establish efficacy in larger and more diverse samples, address dosing considerations, improve blinding, and provide information on mechanisms of action and moderators of clinical response. Head-to-head comparisons with...
Am J Psychiatry
2025
Aaron Wolfgang, Vetisha L. McClair, Paula P. Schnurr et al.
6 citations
Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.
Journal of Psychedelic Studies
February 5, 2024
Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower
1 citation
Abstract In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while...
Journal of Psychedelic Studies
December 14, 2023
Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower
1 citation
AbstractAssociated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25–58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a...
Current Psychiatry Reports
October 1, 2023
Aaron Wolfgang, Charles W Hoge
15 citations
This review discusses the current and projected landscape of psychedelic-assisted therapy (PAT), with a focus on clinical, legal, and implementation considerations in Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. 3,4-Methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted therapy have shown promising outcomes in efficacy, safety, tolerability, and...
Journal of Medical Ethics
May 30, 2023
Scott Hoener, Aaron Wolfgang, David A. Nissan et al.
6 citations
Psychedelic treatments, particularly 3,4-methylenedioxymethamphetamine (MDMA)-assisted and psilocybin-assisted therapies, have recently seen renewed interest in their clinical potential to treat various mental health conditions. Clinical trials for both MDMA-assisted and psilocybin-assisted therapies have shown to be highly efficacious for post-traumatic stress disorder and major depression....
Military Medicine
December 24, 2022
Joshua C. Gray, Mikela A. Murphy, Sierra Carter et al.
10 citations
ABSTRACT Introduction Posttraumatic stress disorder (PTSD) and depression are common in service members and veterans, and the response to currently available treatments is often modest at best. Recent studies suggest potential benefit with psychedelic-assisted therapies (PATs), particularly 3,4-methylenedioxymethamphetamine-assisted therapy for PTSD and psilocybin-assisted therapy for...
Cureus
June 28, 2022
Ann M. Inouye, Aaron Wolfgang
5 citations
The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD). A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose...
Biol Psychiatry
August 1, 2021
Luke G. Petry, Monica Sharma, Aaron Wolfgang et al.
4 citations
Any Questions? A Sober Look at MDMA.